Welcome to Somaxon Pharmaceuticals

Somaxon is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.

To date, we have in-licensed two products. Our lead product, SILENOR™ (doxepin HCl tablets), is in Phase III clinical trials for the treatment of insomnia. Our product nalmefene HCl is in a Phase II/III clinical trial for the treatment of pathological gambling and a Phase II clinical trial for smoking cessation.

We intend to continue to build a portfolio of product candidates that target psychiatric and neurological diseases and disorders, focusing on products that are currently commercialized outside the United States, approved in the United States but with significant commercial potential for proprietary new uses, new dosages or alternative delivery systems, or in late stages of clinical development.

Latest News

May 7, 2008
CLINICAL DATA ON SOMAXON PHARMACEUTICALS’ PRODUCT CANDIDATE FOR THE TREATMENT OF INSOMNIA PRESENTED AT AMERICAN PSYCHIATRIC ASSOCIATION ANNUAL MEETING (.pdf)

May 6, 2008
SOMAXON PHARMACEUTICALS REPORTS 2008 FIRST QUARTER FINANCIAL RESULTS (.pdf)

Join Our Mailing List

Please join our mailing list if you wish to receive news regarding Somaxon and its products.